These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 34409786

  • 1. Colistin plus Sulbactam or Fosfomycin against Carbapenem-Resistant Acinetobacter baumannii: Improved Efficacy or Decreased Risk of Nephrotoxicity?
    Saelim W, Changpradub D, Thunyaharn S, Juntanawiwat P, Nulsopapon P, Santimaleeworagun W.
    Infect Chemother; 2021 Mar; 53(1):128-140. PubMed ID: 34409786
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial Susceptibility among Colistin, Sulbactam, and Fosfomycin and a Synergism Study of Colistin in Combination with Sulbactam or Fosfomycin against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii.
    Leelasupasri S, Santimaleeworagun W, Jitwasinkul T.
    J Pathog; 2018 Mar; 2018():3893492. PubMed ID: 29593912
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases.
    Santimaleeworagun W, Wongpoowarak P, Chayakul P, Pattharachayakul S, Tansakul P, Garey KW.
    Southeast Asian J Trop Med Public Health; 2011 Jul; 42(4):890-900. PubMed ID: 22299471
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic/pharmacodynamic (PK/PD) simulation for dosage optimization of colistin and sitafloxacin, alone and in combination, against carbapenem-, multidrug-, and colistin-resistant Acinetobacter baumannii.
    Rodjun V, Montakantikul P, Houngsaitong J, Jitaree K, Nosoongnoen W.
    Front Microbiol; 2023 Jul; 14():1275909. PubMed ID: 38098659
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Isolates in a Hollow-Fibre Infection Model.
    Mohd Sazlly Lim S, Heffernan A, Naicker S, Wallis S, Roberts JA, Sime FB.
    Antibiotics (Basel); 2022 Nov 09; 11(11):. PubMed ID: 36358238
    [Abstract] [Full Text] [Related]

  • 8. Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece.
    Petropoulou D, Siopi M, Vourli S, Pournaras S.
    Front Cell Infect Microbiol; 2021 Nov 09; 11():814530. PubMed ID: 35127562
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Optimization of Linezolid Dosing Regimens for Treatment of Vancomycin-Resistant Enterococci Infection.
    Santimaleeworagun W, Changpradub D, Hemapanpairoa J, Thunyaharn S.
    Infect Chemother; 2021 Sep 09; 53(3):503-511. PubMed ID: 34405596
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model.
    Fan B, Guan J, Wang X, Cong Y.
    PLoS One; 2016 Sep 09; 11(6):e0157757. PubMed ID: 27315107
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
    Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K, Miller A, Lewis D, O'Donnell J, Chen L, Reinhart H, Srinivasan S, Isaacs R, Altarac D.
    Lancet Infect Dis; 2023 Sep 09; 23(9):1072-1084. PubMed ID: 37182534
    [Abstract] [Full Text] [Related]

  • 15. Non-polymyxin-based combinations as potential alternatives in treatment against carbapenem-resistant Acinetobacter baumannii infections.
    Mohd Sazlly Lim S, Naicker S, Ayfan AK, Zowawi H, Roberts JA, Sime FB.
    Int J Antimicrob Agents; 2020 Oct 09; 56(4):106115. PubMed ID: 32721600
    [Abstract] [Full Text] [Related]

  • 16. Pharmacodynamic Analysis of Meropenem and Fosfomycin Combination Against Carbapenem-Resistant Acinetobacter baumannii in Patients with Normal Renal Clearance: Can It Be a Treatment Option?
    Mohd Sazlly Lim S, Heffernan AJ, Roberts JA, Sime FB.
    Microb Drug Resist; 2021 Apr 09; 27(4):546-552. PubMed ID: 32898467
    [Abstract] [Full Text] [Related]

  • 17. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
    Zhao C, Xie W, Zhang W, Ye Z, Wu H.
    Zhonghua Shao Shang Za Zhi; 2014 Apr 09; 30(2):166-70. PubMed ID: 24989663
    [Abstract] [Full Text] [Related]

  • 18. Semi-mechanistic PK/PD modelling of fosfomycin and sulbactam combination against carbapenem-resistant Acinetobacter baumannii.
    Mohd Sazlly Lim S, Heffernan AJ, Roberts JA, Sime FB.
    Antimicrob Agents Chemother; 2023 May 01; 65(5):. PubMed ID: 33685901
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of colistin mono- and combination therapy against colistin-resistant Acinetobacter baumannii, mechanism of resistance, and clinical outcomes of patients infected with colistin-resistant A. baumannii at a Thai university hospital.
    Lertsrisatit Y, Santimaleeworagun W, Thunyaharn S, Traipattanakul J.
    Infect Drug Resist; 2017 May 01; 10():437-443. PubMed ID: 29200878
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.